Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Total Current Liabilities for 7 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 25.63% year-over-year to $20.4 million, compared with a TTM value of $20.4 million through Dec 2025, down 25.63%, and an annual FY2025 reading of $20.4 million, down 25.63% over the prior year.
  • Total Current Liabilities was $20.4 million for Q4 2025 at Keros Therapeutics, down from $24.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $39.4 million in Q1 2025 and bottomed at $7.5 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $19.7 million, with a median of $17.7 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 110.38% in 2025, while the deepest fall reached 25.63% in 2025.
  • Year by year, Total Current Liabilities stood at $11.8 million in 2021, then surged by 39.68% to $16.5 million in 2022, then soared by 47.3% to $24.4 million in 2023, then grew by 12.62% to $27.4 million in 2024, then dropped by 25.63% to $20.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for KROS at $20.4 million in Q4 2025, $24.1 million in Q3 2025, and $34.7 million in Q2 2025.